



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Prexasertib lactate

Cat. No.:	HY-18174H
CAS No.:	2781996-46-9
Molecular Formula:	C ₂₁ H ₂₅ N ₇ O ₅
Molecular Weight:	455.47
Target:	Checkpoint Kinase (Chk); Apoptosis; DNA/RNA Synthesis
Pathway:	Cell Cycle/DNA Damage; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Prexasertib lactate (LY2606368 lactate) is the lactate form of Prexasertib (HY-18174). Prexasertib lactate is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a K _i of 0.9 nM and an IC ₅₀ of <1 nM. Prexasertib lactate inhibits CHK2 (IC ₅₀ =8 nM) and RSK1 (IC ₅₀ =9 nM). Prexasertib lactate causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib lactate shows potent anti-tumor activity ^{[1][2]} .	
IC₅₀ & Target	Chk1 <1 nM (IC ₅₀)	Chk2 8 nM (IC ₅₀)

CUSTOMER VALIDATION

- Nat Commun. 2019 Aug 2;10(1):3485.
- Thorax. 2021 Jul 5;thoraxjnl-2021-217377.
- Br J Cancer. 2021 Mar 26.
- Oncogene. 2022 Oct 12.
- Cell Biol Toxicol. 2021 Sep 14.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. King C, et al. LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms. Mol Cancer Ther. 2015 Sep;14(9):2004-1
- [2]. Yin Y, et al. Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. Am J Cancer Res. 2017 Mar 1;7(3):473-483.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA